The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
Adaptive Biotechnologies Corp (NASDAQ: ADPT) closed the day trading at $19.72 down -2.95% from the previous closing price of $20.32. In other words, the price has decreased by -$2.95 from its previous closing price. On the day, 1.87 million shares were traded. ADPT stock price reached its highest trading level at $20.34 during the session, while it also had its lowest trading level at $19.4.
Ratios:
For a better understanding of ADPT, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.26 and its Current Ratio is at 3.38. In the meantime, Its Debt-to-Equity ratio is 1.05 whereas as Long-Term Debt/Eq ratio is at 0.99.
Upgrades & Downgrades
In the most recent recommendation for this company, Guggenheim on September 30, 2025, initiated with a Buy rating and assigned the stock a target price of $20.
On June 18, 2025, Craig Hallum started tracking the stock assigning a Buy rating and target price of $15.
Goldman Upgraded its Neutral to Buy on March 21, 2025, while the target price for the stock was maintained at $9.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 26 ’25 when Chad Robins bought 35,736 shares for $19.72 per share.
BENZENO SHARON sold 308,477 shares of ADPT for $5,216,346 on Nov 21 ’25. The Chief Commercial Ofc Imm Med now owns 296,791 shares after completing the transaction at $16.91 per share. On Nov 20 ’25, another insider, BENZENO SHARON, who serves as the Chief Commercial Ofc Imm Med of the company, sold 297,925 shares for $16.54 each. As a result, the insider received 4,927,680 and left with 296,791 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADPT now has a Market Capitalization of 3010557440 and an Enterprise Value of 3011247616. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.91 while its Price-to-Book (P/B) ratio in mrq is 14.72. Its current Enterprise Value per Revenue stands at 11.914 whereas that against EBITDA is -50.103.
Stock Price History:
The Beta on a monthly basis for ADPT is 2.17, which has changed by 2.3198652 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, ADPT has reached a high of $20.76, while it has fallen to a 52-week low of $5.29. The 50-Day Moving Average of the stock is 25.44%, while the 200-Day Moving Average is calculated to be 73.86%.
Shares Statistics:
Over the past 3-months, ADPT traded about 2.03M shares per day on average, while over the past 10 days, ADPT traded about 2846860 shares per day. A total of 152.58M shares are outstanding, with a floating share count of 146.49M. Insiders hold about 3.91% of the company’s shares, while institutions hold 93.91% stake in the company. Shares short for ADPT as of 1763078400 were 10368382 with a Short Ratio of 5.11, compared to 1760486400 on 9027063. Therefore, it implies a Short% of Shares Outstanding of 10368382 and a Short% of Float of 8.6899996.
Earnings Estimates
The stock of Adaptive Biotechnologies Corp (ADPT) is currently in the spotlight, with 7.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.17, with high estimates of -$0.15 and low estimates of -$0.19.
Analysts are recommending an EPS of between -$0.46 and -$0.51 for the fiscal current year, implying an average EPS of -$0.49. EPS for the following year is -$0.57, with 7.0 analysts recommending between -$0.51 and -$0.65.
Revenue Estimates
7 analysts predict $59.28M in revenue for. The current quarter. It ranges from a high estimate of $61.5M to a low estimate of $57.7M. As of. The current estimate, Adaptive Biotechnologies Corp’s year-ago sales were $47.46MFor the next quarter, 7 analysts are estimating revenue of $59.3M. There is a high estimate of $63.1M for the next quarter, whereas the lowest estimate is $55.08M.
A total of 8 analysts have provided revenue estimates for ADPT’s current fiscal year. The highest revenue estimate was $266.8M, while the lowest revenue estimate was $263.04M, resulting in an average revenue estimate of $264.63M. In the same quarter a year ago, actual revenue was $178.96MBased on 8 analysts’ estimates, the company’s revenue will be $267.68M in the next fiscal year. The high estimate is $275.5M and the low estimate is $255.7M.
